|
Name |
[(1R,3Z,6R,7Z,9S,11Z,13R,14S,16R,17S,18R,19S)-19-benzyl-7,9,16,17-tetramethyl-2,5,21-trioxo-15-oxa-20-azatetracyclo[11.8.0.01,18.014,16]henicosa-3,7,11-trien-6-yl] acetate
|
Molecular Formula | C32H37NO6 | |
IUPAC Name* |
[(1R,3Z,6R,7Z,9S,11Z,13R,14S,16R,17S,18R,19S)-19-benzyl-7,9,16,17-tetramethyl-2,5,21-trioxo-15-oxa-20-azatetracyclo[11.8.0.01,18.014,16]henicosa-3,7,11-trien-6-yl] acetate
|
|
SMILES |
C[C@H]/1C/C=C\[C@H]2[C@H]3[C@](O3)([C@H]([C@@H]4[C@@]2(C(=O)/C=C\C(=O)[C@@H](/C(=C1)/C)OC(=O)C)C(=O)N[C@H]4CC5=CC=CC=C5)C)C
|
|
InChI |
InChI=1S/C32H37NO6/c1-18-10-9-13-23-29-31(5,39-29)20(3)27-24(17-22-11-7-6-8-12-22)33-30(37)32(23,27)26(36)15-14-25(35)28(19(2)16-18)38-21(4)34/h6-9,11-16,18,20,23-24,27-29H,10,17H2,1-5H3,(H,33,37)/b13-9-,15-14-,19-16-/t18-,20-,23-,24-,27-,28+,29-,31+,32+/m0/s1
|
|
InChIKey |
AZWOSJCABFILKS-NVRMHEMHSA-N
|
|
Synonyms |
Cytochalasin K; 79648-72-9
|
|
CAS | NA | |
PubChem CID | 102115580 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 531.6 | ALogp: | 4.2 |
HBD: | 1 | HBA: | 6 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 102.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 39 | QED Weighted: | 0.265 |
Caco-2 Permeability: | -4.796 | MDCK Permeability: | 0.00002270 |
Pgp-inhibitor: | 0.999 | Pgp-substrate: | 0.272 |
Human Intestinal Absorption (HIA): | 0.127 | 20% Bioavailability (F20%): | 0.508 |
30% Bioavailability (F30%): | 0.979 |
Blood-Brain-Barrier Penetration (BBB): | 0.789 | Plasma Protein Binding (PPB): | 87.03% |
Volume Distribution (VD): | 0.622 | Fu: | 10.15% |
CYP1A2-inhibitor: | 0.083 | CYP1A2-substrate: | 0.091 |
CYP2C19-inhibitor: | 0.899 | CYP2C19-substrate: | 0.646 |
CYP2C9-inhibitor: | 0.911 | CYP2C9-substrate: | 0.018 |
CYP2D6-inhibitor: | 0.178 | CYP2D6-substrate: | 0.042 |
CYP3A4-inhibitor: | 0.883 | CYP3A4-substrate: | 0.357 |
Clearance (CL): | 6.871 | Half-life (T1/2): | 0.806 |
hERG Blockers: | 0.066 | Human Hepatotoxicity (H-HT): | 0.521 |
Drug-inuced Liver Injury (DILI): | 0.234 | AMES Toxicity: | 0.174 |
Rat Oral Acute Toxicity: | 0.487 | Maximum Recommended Daily Dose: | 0.897 |
Skin Sensitization: | 0.798 | Carcinogencity: | 0.433 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
Respiratory Toxicity: | 0.97 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004473 | 0.669 | D01TSI | 0.269 | ||||
ENC002828 | 0.612 | D0V3ZA | 0.262 | ||||
ENC002202 | 0.603 | D0SP3D | 0.262 | ||||
ENC002762 | 0.576 | D09NNH | 0.255 | ||||
ENC003712 | 0.575 | D0C4RB | 0.240 | ||||
ENC001886 | 0.566 | D0W7RJ | 0.240 | ||||
ENC001865 | 0.562 | D06CWH | 0.240 | ||||
ENC002120 | 0.557 | D00OAY | 0.239 | ||||
ENC006059 | 0.553 | D07DIM | 0.239 | ||||
ENC004341 | 0.553 | D0O5WP | 0.238 |